Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Vericel Corporation

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving landscape of corporate finance, understanding Selling, General, and Administrative (SG&A) expenses is crucial for evaluating a company's operational efficiency. This analysis juxtaposes the SG&A expenses of Walgreens Boots Alliance, Inc. and Vericel Corporation from 2014 to 2023.

Walgreens Boots Alliance, a global leader in retail pharmacy, consistently reported SG&A expenses exceeding $17 billion annually, peaking at approximately $28 billion in 2024. This reflects its expansive operations and market reach. In contrast, Vericel Corporation, a biopharmaceutical company, exhibited a steady growth in SG&A expenses, starting at $13.8 million in 2014 and reaching $120.9 million by 2023, highlighting its strategic investments in growth and innovation.

The data reveals a stark contrast in scale and growth trajectory, offering insights into each company's strategic priorities and market positioning. Missing data for Vericel in 2024 suggests a need for further analysis to understand future trends.